Back to Search
Start Over
Embolic Protection and Platelet Inhibition During Renal Artery Stenting
- Source :
- Circulation. 117:2752-2760
- Publication Year :
- 2008
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2008.
-
Abstract
- Background— Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown. Methods and Results— One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease–derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined ( P P P P =0.08). An interaction was observed between abciximab and embolic protection ( P P Conclusions— Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.
- Subjects :
- medicine.medical_specialty
Creatinine
Kidney
business.industry
medicine.medical_treatment
Renal function
Stent
Embolic Protection Devices
chemistry.chemical_compound
medicine.anatomical_structure
chemistry
Physiology (medical)
Internal medicine
medicine.artery
Angioplasty
medicine
Cardiology
Abciximab
Renal artery
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 15244539 and 00097322
- Volume :
- 117
- Database :
- OpenAIRE
- Journal :
- Circulation
- Accession number :
- edsair.doi...........c02edfd4e1bbb126885dff138e67ac3d